David focuses his practice on patent counseling, portfolio development, and intellectual property strategy for life sciences companies across a wide range of technologies. Recognized internationally for his work securing patent protection for repurposed drugs, he advises clients from early-stage innovation through commercialization, helping them protect valuable technologies and maximize portfolio value in competitive global markets.

His decades-long experience encompasses patent drafting and prosecution, patent portfolio analysis, freedom-to-operate and noninfringement assessments, intellectual property licensing, post-grant and contested proceedings, portfolio monetization initiatives, and intellectual property support for mergers and acquisitions. He is also well versed in the relationship between the U.S. patent system and FDA regulatory processes, providing practical guidance informed by both legal and business considerations.

His pro bono efforts are presently focused on protecting therapeutics for rare, childhood diseases.

Drawing on an advanced scientific background in molecular biology, David works with innovations involving biologics, antibodies, stem cells, cell and gene therapies, pharmaceuticals, tissue engineering, nucleic acids, genetically modified organisms, ocular drug delivery platforms, fungal-based foods and ingredients, proteomics, renewable energy technologies, and other emerging technologies.